Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer

IMPORTANCE: Among patients with esophagogastric cancers, only individuals who present with known features of heritable cancer syndromes are referred for genetic testing. Broader testing might identify additional patients with germline alterations. OBJECTIVES: To examine the prevalence of likely path...

Full description

Saved in:

Bibliographic Details
Published in:	JAMA Network Open Vol. 4; no. 7; p. e2114753
Main Authors:	Ku, Geoffrey Y, Kemel, Yelena, Maron, Steve B, Chou, Joanne F, Ravichandran, Vignesh, Shameer, Zarina, Maio, Anna, Won, Elizabeth S, Kelsen, David P, Ilson, David H, Capanu, Marinela, Strong, Vivian E, Molena, Daniela, Sihag, Smita, Jones, David R, Coit, Daniel G, Tuvy, Yaelle, Cowie, Kendall, Solit, David B, Schultz, Nikolaus, Hechtman, Jaclyn F, Offit, Kenneth, Joseph, Vijai, Mandelker, Diana, Janjigian, Yelena Y, Stadler, Zsofia K
Format:	Journal Article
Language:	English
Published:	United States American Medical Association 01.07.2021
Subjects:	Adolescent Adult Aged Aged, 80 and over Cross-Sectional Studies Esophageal cancer Esophageal Neoplasms - epidemiology Esophageal Neoplasms - genetics Female Gastric cancer Germ-Line Mutation - genetics Humans Male Middle Aged Oncology Online Only Original Investigation Prevalence Whole Genome Sequencing - methods Whole Genome Sequencing - statistics & numerical data
ISSN:	2574-3805, 2574-3805
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	IMPORTANCE: Among patients with esophagogastric cancers, only individuals who present with known features of heritable cancer syndromes are referred for genetic testing. Broader testing might identify additional patients with germline alterations. OBJECTIVES: To examine the prevalence of likely pathogenic or pathogenic (LP/P) germline alterations among patients with esophagogastric cancer and to assess associations between germline variant prevalence and demographic and clinicopathologic features. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study was performed at a tertiary referral cancer center from January 1, 2014, to December 31, 2019, in 515 patients with esophagogastric cancer who consented to tumor and blood sequencing. MAIN OUTCOMES AND MEASURES: Presence or absence of LP/P variants in up to 88 genes associated with cancer predisposition syndromes as identified by targeted sequencing (Memorial Sloan Kettering–Integrated Mutation Profiling of Actionable Cancer Targets). RESULTS: Among 515 patients (median age, 59 years; range, 18-87 years; 368 [71.5%] male; 398 [77.3%] White), 243 (47.2%) had gastric cancer, 111 (21.6%) had gastroesophageal junction (GEJ) cancer, and 161 (31.3%) had esophageal cancer. A total of 48 patients with gastric cancer (19.8%), 16 (14.4%) with GEJ cancer, and 17 (10.6%) with esophageal cancer had LP/P germline variants. The number of LP/P variants in high- and moderate-penetrance genes was significantly higher in patients with gastric cancer (29 [11.9%]; 95% CI, 8.1%-16.7%) vs patients with esophageal cancer (8 [5.0%]; 95% CI, 2.2%-9.6%; P = .03), and the difference was greater for high-penetrance germline alterations in patients with gastric cancer (25 [10.3%]; 95% CI, 6.8%-14.8%) vs in patients with esophageal cancer (3 [1.9%]; 95% CI, 0.38%-5.3%; P = .001). The most frequent high- and moderate-penetrance LP/P alterations were in BRCA1/2 (14 [2.7%]), ATM (11 [2.1%]), CDH1 (6 [1.2%]), and MSH2 (4 [0.8%]). Those with early-onset disease (≤50 years of age at diagnosis) were more likely to harbor an LP/P germline variant (29 [21.0%]; 95% CI, 14.5%-28.8%) vs those with late-onset disease (patients >50 years of age at diagnosis) (52 [13.8%]; 95% CI, 10.5%-17.7%; P = .046). ATM LP/P variants occurred in 6 patients (4.3%; 95% CI, 1.6%-9.1%) with early-onset esophagogastric cancer vs 5 (1.3%; 95% CI, 0.4%-3.1%; P = .08) of those with late-onset esophagogastric cancer. CONCLUSIONS AND RELEVANCE: These results suggest that pathogenic germline variants are enriched in gastric and early-onset esophagogastric cancer and that germline testing should be considered in these populations. The role of ATM alterations in esophagogastric cancer risk warrants further investigation.
AbstractList	Among patients with esophagogastric cancers, only individuals who present with known features of heritable cancer syndromes are referred for genetic testing. Broader testing might identify additional patients with germline alterations. To examine the prevalence of likely pathogenic or pathogenic (LP/P) germline alterations among patients with esophagogastric cancer and to assess associations between germline variant prevalence and demographic and clinicopathologic features. This cross-sectional study was performed at a tertiary referral cancer center from January 1, 2014, to December 31, 2019, in 515 patients with esophagogastric cancer who consented to tumor and blood sequencing. Presence or absence of LP/P variants in up to 88 genes associated with cancer predisposition syndromes as identified by targeted sequencing (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets). Among 515 patients (median age, 59 years; range, 18-87 years; 368 [71.5%] male; 398 [77.3%] White), 243 (47.2%) had gastric cancer, 111 (21.6%) had gastroesophageal junction (GEJ) cancer, and 161 (31.3%) had esophageal cancer. A total of 48 patients with gastric cancer (19.8%), 16 (14.4%) with GEJ cancer, and 17 (10.6%) with esophageal cancer had LP/P germline variants. The number of LP/P variants in high- and moderate-penetrance genes was significantly higher in patients with gastric cancer (29 [11.9%]; 95% CI, 8.1%-16.7%) vs patients with esophageal cancer (8 [5.0%]; 95% CI, 2.2%-9.6%; P = .03), and the difference was greater for high-penetrance germline alterations in patients with gastric cancer (25 [10.3%]; 95% CI, 6.8%-14.8%) vs in patients with esophageal cancer (3 [1.9%]; 95% CI, 0.38%-5.3%; P = .001). The most frequent high- and moderate-penetrance LP/P alterations were in BRCA1/2 (14 [2.7%]), ATM (11 [2.1%]), CDH1 (6 [1.2%]), and MSH2 (4 [0.8%]). Those with early-onset disease (≤50 years of age at diagnosis) were more likely to harbor an LP/P germline variant (29 [21.0%]; 95% CI, 14.5%-28.8%) vs those with late-onset disease (patients >50 years of age at diagnosis) (52 [13.8%]; 95% CI, 10.5%-17.7%; P = .046). ATM LP/P variants occurred in 6 patients (4.3%; 95% CI, 1.6%-9.1%) with early-onset esophagogastric cancer vs 5 (1.3%; 95% CI, 0.4%-3.1%; P = .08) of those with late-onset esophagogastric cancer. These results suggest that pathogenic germline variants are enriched in gastric and early-onset esophagogastric cancer and that germline testing should be considered in these populations. The role of ATM alterations in esophagogastric cancer risk warrants further investigation. This genetic association study examines the prevalence of likely pathogenic or pathogenic germline alterations among patients with esophagogastric cancer and assesses associations between germline variant prevalence and demographic and clinicopathologic features. IMPORTANCE: Among patients with esophagogastric cancers, only individuals who present with known features of heritable cancer syndromes are referred for genetic testing. Broader testing might identify additional patients with germline alterations. OBJECTIVES: To examine the prevalence of likely pathogenic or pathogenic (LP/P) germline alterations among patients with esophagogastric cancer and to assess associations between germline variant prevalence and demographic and clinicopathologic features. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study was performed at a tertiary referral cancer center from January 1, 2014, to December 31, 2019, in 515 patients with esophagogastric cancer who consented to tumor and blood sequencing. MAIN OUTCOMES AND MEASURES: Presence or absence of LP/P variants in up to 88 genes associated with cancer predisposition syndromes as identified by targeted sequencing (Memorial Sloan Kettering–Integrated Mutation Profiling of Actionable Cancer Targets). RESULTS: Among 515 patients (median age, 59 years; range, 18-87 years; 368 [71.5%] male; 398 [77.3%] White), 243 (47.2%) had gastric cancer, 111 (21.6%) had gastroesophageal junction (GEJ) cancer, and 161 (31.3%) had esophageal cancer. A total of 48 patients with gastric cancer (19.8%), 16 (14.4%) with GEJ cancer, and 17 (10.6%) with esophageal cancer had LP/P germline variants. The number of LP/P variants in high- and moderate-penetrance genes was significantly higher in patients with gastric cancer (29 [11.9%]; 95% CI, 8.1%-16.7%) vs patients with esophageal cancer (8 [5.0%]; 95% CI, 2.2%-9.6%; P = .03), and the difference was greater for high-penetrance germline alterations in patients with gastric cancer (25 [10.3%]; 95% CI, 6.8%-14.8%) vs in patients with esophageal cancer (3 [1.9%]; 95% CI, 0.38%-5.3%; P = .001). The most frequent high- and moderate-penetrance LP/P alterations were in BRCA1/2 (14 [2.7%]), ATM (11 [2.1%]), CDH1 (6 [1.2%]), and MSH2 (4 [0.8%]). Those with early-onset disease (≤50 years of age at diagnosis) were more likely to harbor an LP/P germline variant (29 [21.0%]; 95% CI, 14.5%-28.8%) vs those with late-onset disease (patients >50 years of age at diagnosis) (52 [13.8%]; 95% CI, 10.5%-17.7%; P = .046). ATM LP/P variants occurred in 6 patients (4.3%; 95% CI, 1.6%-9.1%) with early-onset esophagogastric cancer vs 5 (1.3%; 95% CI, 0.4%-3.1%; P = .08) of those with late-onset esophagogastric cancer. CONCLUSIONS AND RELEVANCE: These results suggest that pathogenic germline variants are enriched in gastric and early-onset esophagogastric cancer and that germline testing should be considered in these populations. The role of ATM alterations in esophagogastric cancer risk warrants further investigation. Among patients with esophagogastric cancers, only individuals who present with known features of heritable cancer syndromes are referred for genetic testing. Broader testing might identify additional patients with germline alterations.ImportanceAmong patients with esophagogastric cancers, only individuals who present with known features of heritable cancer syndromes are referred for genetic testing. Broader testing might identify additional patients with germline alterations.To examine the prevalence of likely pathogenic or pathogenic (LP/P) germline alterations among patients with esophagogastric cancer and to assess associations between germline variant prevalence and demographic and clinicopathologic features.ObjectivesTo examine the prevalence of likely pathogenic or pathogenic (LP/P) germline alterations among patients with esophagogastric cancer and to assess associations between germline variant prevalence and demographic and clinicopathologic features.This cross-sectional study was performed at a tertiary referral cancer center from January 1, 2014, to December 31, 2019, in 515 patients with esophagogastric cancer who consented to tumor and blood sequencing.Design, Setting, and ParticipantsThis cross-sectional study was performed at a tertiary referral cancer center from January 1, 2014, to December 31, 2019, in 515 patients with esophagogastric cancer who consented to tumor and blood sequencing.Presence or absence of LP/P variants in up to 88 genes associated with cancer predisposition syndromes as identified by targeted sequencing (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets).Main Outcomes and MeasuresPresence or absence of LP/P variants in up to 88 genes associated with cancer predisposition syndromes as identified by targeted sequencing (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets).Among 515 patients (median age, 59 years; range, 18-87 years; 368 [71.5%] male; 398 [77.3%] White), 243 (47.2%) had gastric cancer, 111 (21.6%) had gastroesophageal junction (GEJ) cancer, and 161 (31.3%) had esophageal cancer. A total of 48 patients with gastric cancer (19.8%), 16 (14.4%) with GEJ cancer, and 17 (10.6%) with esophageal cancer had LP/P germline variants. The number of LP/P variants in high- and moderate-penetrance genes was significantly higher in patients with gastric cancer (29 [11.9%]; 95% CI, 8.1%-16.7%) vs patients with esophageal cancer (8 [5.0%]; 95% CI, 2.2%-9.6%; P = .03), and the difference was greater for high-penetrance germline alterations in patients with gastric cancer (25 [10.3%]; 95% CI, 6.8%-14.8%) vs in patients with esophageal cancer (3 [1.9%]; 95% CI, 0.38%-5.3%; P = .001). The most frequent high- and moderate-penetrance LP/P alterations were in BRCA1/2 (14 [2.7%]), ATM (11 [2.1%]), CDH1 (6 [1.2%]), and MSH2 (4 [0.8%]). Those with early-onset disease (≤50 years of age at diagnosis) were more likely to harbor an LP/P germline variant (29 [21.0%]; 95% CI, 14.5%-28.8%) vs those with late-onset disease (patients >50 years of age at diagnosis) (52 [13.8%]; 95% CI, 10.5%-17.7%; P = .046). ATM LP/P variants occurred in 6 patients (4.3%; 95% CI, 1.6%-9.1%) with early-onset esophagogastric cancer vs 5 (1.3%; 95% CI, 0.4%-3.1%; P = .08) of those with late-onset esophagogastric cancer.ResultsAmong 515 patients (median age, 59 years; range, 18-87 years; 368 [71.5%] male; 398 [77.3%] White), 243 (47.2%) had gastric cancer, 111 (21.6%) had gastroesophageal junction (GEJ) cancer, and 161 (31.3%) had esophageal cancer. A total of 48 patients with gastric cancer (19.8%), 16 (14.4%) with GEJ cancer, and 17 (10.6%) with esophageal cancer had LP/P germline variants. The number of LP/P variants in high- and moderate-penetrance genes was significantly higher in patients with gastric cancer (29 [11.9%]; 95% CI, 8.1%-16.7%) vs patients with esophageal cancer (8 [5.0%]; 95% CI, 2.2%-9.6%; P = .03), and the difference was greater for high-penetrance germline alterations in patients with gastric cancer (25 [10.3%]; 95% CI, 6.8%-14.8%) vs in patients with esophageal cancer (3 [1.9%]; 95% CI, 0.38%-5.3%; P = .001). The most frequent high- and moderate-penetrance LP/P alterations were in BRCA1/2 (14 [2.7%]), ATM (11 [2.1%]), CDH1 (6 [1.2%]), and MSH2 (4 [0.8%]). Those with early-onset disease (≤50 years of age at diagnosis) were more likely to harbor an LP/P germline variant (29 [21.0%]; 95% CI, 14.5%-28.8%) vs those with late-onset disease (patients >50 years of age at diagnosis) (52 [13.8%]; 95% CI, 10.5%-17.7%; P = .046). ATM LP/P variants occurred in 6 patients (4.3%; 95% CI, 1.6%-9.1%) with early-onset esophagogastric cancer vs 5 (1.3%; 95% CI, 0.4%-3.1%; P = .08) of those with late-onset esophagogastric cancer.These results suggest that pathogenic germline variants are enriched in gastric and early-onset esophagogastric cancer and that germline testing should be considered in these populations. The role of ATM alterations in esophagogastric cancer risk warrants further investigation.Conclusions and RelevanceThese results suggest that pathogenic germline variants are enriched in gastric and early-onset esophagogastric cancer and that germline testing should be considered in these populations. The role of ATM alterations in esophagogastric cancer risk warrants further investigation. Importance Among patients with esophagogastric cancers, only individuals who present with known features of heritable cancer syndromes are referred for genetic testing. Broader testing might identify additional patients with germline alterations. Objectives To examine the prevalence of likely pathogenic or pathogenic (LP/P) germline alterations among patients with esophagogastric cancer and to assess associations between germline variant prevalence and demographic and clinicopathologic features. Design, Setting, and Participants This cross-sectional study was performed at a tertiary referral cancer center from January 1, 2014, to December 31, 2019, in 515 patients with esophagogastric cancer who consented to tumor and blood sequencing. Main Outcomes and Measures Presence or absence of LP/P variants in up to 88 genes associated with cancer predisposition syndromes as identified by targeted sequencing (Memorial Sloan Kettering–Integrated Mutation Profiling of Actionable Cancer Targets). Results Among 515 patients (median age, 59 years; range, 18-87 years; 368 [71.5%] male; 398 [77.3%] White), 243 (47.2%) had gastric cancer, 111 (21.6%) had gastroesophageal junction (GEJ) cancer, and 161 (31.3%) had esophageal cancer. A total of 48 patients with gastric cancer (19.8%), 16 (14.4%) with GEJ cancer, and 17 (10.6%) with esophageal cancer had LP/P germline variants. The number of LP/P variants in high- and moderate-penetrance genes was significantly higher in patients with gastric cancer (29 [11.9%]; 95% CI, 8.1%-16.7%) vs patients with esophageal cancer (8 [5.0%]; 95% CI, 2.2%-9.6%;P = .03), and the difference was greater for high-penetrance germline alterations in patients with gastric cancer (25 [10.3%]; 95% CI, 6.8%-14.8%) vs in patients with esophageal cancer (3 [1.9%]; 95% CI, 0.38%-5.3%;P = .001). The most frequent high- and moderate-penetrance LP/P alterations were inBRCA1/2(14 [2.7%]),ATM(11 [2.1%]),CDH1(6 [1.2%]), andMSH2(4 [0.8%]). Those with early-onset disease (≤50 years of age at diagnosis) were more likely to harbor an LP/P germline variant (29 [21.0%]; 95% CI, 14.5%-28.8%) vs those with late-onset disease (patients >50 years of age at diagnosis) (52 [13.8%]; 95% CI, 10.5%-17.7%;P = .046).ATMLP/P variants occurred in 6 patients (4.3%; 95% CI, 1.6%-9.1%) with early-onset esophagogastric cancer vs 5 (1.3%; 95% CI, 0.4%-3.1%;P = .08) of those with late-onset esophagogastric cancer. Conclusions and Relevance These results suggest that pathogenic germline variants are enriched in gastric and early-onset esophagogastric cancer and that germline testing should be considered in these populations. The role ofATMalterations in esophagogastric cancer risk warrants further investigation.
Author	Schultz, Nikolaus Capanu, Marinela Ravichandran, Vignesh Solit, David B Tuvy, Yaelle Hechtman, Jaclyn F Offit, Kenneth Kelsen, David P Won, Elizabeth S Maron, Steve B Molena, Daniela Janjigian, Yelena Y Jones, David R Maio, Anna Sihag, Smita Kemel, Yelena Ilson, David H Coit, Daniel G Mandelker, Diana Strong, Vivian E Ku, Geoffrey Y Shameer, Zarina Chou, Joanne F Joseph, Vijai Cowie, Kendall Stadler, Zsofia K
AuthorAffiliation	6 Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 9 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 2 Department of Medicine, Weill Cornell Medical College, New York, New York 7 Department of Surgery, Weill Cornell Medical College, New York, New York 8 Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 4 Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 3 Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, New York 1 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 5 Now with AstraZeneca, Gaithersburg, Maryland
AuthorAffiliation_xml	– name: 5 Now with AstraZeneca, Gaithersburg, Maryland – name: 1 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York – name: 7 Department of Surgery, Weill Cornell Medical College, New York, New York – name: 2 Department of Medicine, Weill Cornell Medical College, New York, New York – name: 8 Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York – name: 4 Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York – name: 6 Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York – name: 9 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York – name: 10 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York – name: 3 Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, New York
Author_xml	– sequence: 1 givenname: Geoffrey Y surname: Ku fullname: Ku, Geoffrey Y – sequence: 2 givenname: Yelena surname: Kemel fullname: Kemel, Yelena – sequence: 3 givenname: Steve B surname: Maron fullname: Maron, Steve B – sequence: 4 givenname: Joanne F surname: Chou fullname: Chou, Joanne F – sequence: 5 givenname: Vignesh surname: Ravichandran fullname: Ravichandran, Vignesh – sequence: 6 givenname: Zarina surname: Shameer fullname: Shameer, Zarina – sequence: 7 givenname: Anna surname: Maio fullname: Maio, Anna – sequence: 8 givenname: Elizabeth S surname: Won fullname: Won, Elizabeth S – sequence: 9 givenname: David P surname: Kelsen fullname: Kelsen, David P – sequence: 10 givenname: David H surname: Ilson fullname: Ilson, David H – sequence: 11 givenname: Marinela surname: Capanu fullname: Capanu, Marinela – sequence: 12 givenname: Vivian E surname: Strong fullname: Strong, Vivian E – sequence: 13 givenname: Daniela surname: Molena fullname: Molena, Daniela – sequence: 14 givenname: Smita surname: Sihag fullname: Sihag, Smita – sequence: 15 givenname: David R surname: Jones fullname: Jones, David R – sequence: 16 givenname: Daniel G surname: Coit fullname: Coit, Daniel G – sequence: 17 givenname: Yaelle surname: Tuvy fullname: Tuvy, Yaelle – sequence: 18 givenname: Kendall surname: Cowie fullname: Cowie, Kendall – sequence: 19 givenname: David B surname: Solit fullname: Solit, David B – sequence: 20 givenname: Nikolaus surname: Schultz fullname: Schultz, Nikolaus – sequence: 21 givenname: Jaclyn F surname: Hechtman fullname: Hechtman, Jaclyn F – sequence: 22 givenname: Kenneth surname: Offit fullname: Offit, Kenneth – sequence: 23 givenname: Vijai surname: Joseph fullname: Joseph, Vijai – sequence: 24 givenname: Diana surname: Mandelker fullname: Mandelker, Diana – sequence: 25 givenname: Yelena Y surname: Janjigian fullname: Janjigian, Yelena Y – sequence: 26 givenname: Zsofia K surname: Stadler fullname: Stadler, Zsofia K
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/34251444$$D View this record in MEDLINE/PubMed
BookMark	eNqNkc1uEzEUhS1UREvpC7BAI7phM8H_9rBAraJSkCqo1LA2N44zdZixgz3Tqm-P07RVyYqVLfmcz-fe8xrthRgcQu8JnhCMyccV9BDccBvT77h2YUIxJRPClWAv0AEVitdMY7H37L6PjnJeYYwpJqyR4hXaZ5wKwjk_QL8uk7uBzgXrqriszl3qOx9cddoNLsHgY8hVDNUMUusGt6hmYx9T_T2mHrrqyv0Zi9OHduM9y3F9DW1sIQ_J22oKBZreoJdL6LI7ejgP0c8vZ7Pp1_rix_m36elFDVyxoRZuLsWCCG5BzhvN57qxlnMgykqilWQNt0sNgoDkTjBFFDQMBCbYYi0IZYfo85a7Hue9W1gXhgSdWSffQ7ozEbz59yX4a9PGG6OpkljrAvjwAEixjJUH0_tsXdeVdccxGyoEllRhyYr0eEe6imMKZTxDpdS6wYVZVO-eJ3qK8rj8IjjZCmyKOSe3NNYP9zsvAX1nCDabys1O5WZTubmvvCA-7SAef_kv89utuUiefFRp0hDM_gIEHcDt
CitedBy_id	crossref_primary_10_1186_s13073_022_01068_0 crossref_primary_10_1200_EDBK_390522 crossref_primary_10_3748_wjg_v30_i38_4221 crossref_primary_10_1093_jnci_djad186 crossref_primary_10_1001_jamanetworkopen_2021_14789 crossref_primary_10_1016_j_heliyon_2024_e29867 crossref_primary_10_1093_jnci_djac024 crossref_primary_10_3390_ijerph20043640 crossref_primary_10_1016_j_hoc_2024_04_002 crossref_primary_10_1038_s41698_025_01030_4 crossref_primary_10_1093_oncolo_oyaf141 crossref_primary_10_1200_PO_24_00620 crossref_primary_10_1007_s10620_022_07387_x crossref_primary_10_3389_fgene_2023_1180500 crossref_primary_10_1016_j_hoc_2024_01_006
Cites_doi	10.1001/jama.2018.6228 10.18632/oncotarget.v6i38 10.1038/sj.bjc.6600562 10.1097/MOG.0000000000000115 10.1086/302746 10.1056/NEJMoa1903387 10.1200/JCO.19.02931 10.1056/NEJMoa1911440 10.1038/gim.2015.30 10.1038/gim.2016.190 10.1056/NEJMoa1706450 10.1016/j.jmoldx.2014.12.006 10.1038/nature20805 10.1038/s41436-019-0463-8 10.1016/S1470-2045(14)71016-2 10.1007/s10689-011-9506-2 10.1056/NEJMoa1810858 10.1038/gim.2014.147 10.1093/jnci/djy024 10.1016/S0959-8049(99)00135-5 10.1093/jnci/91.15.1310 10.3322/caac.v68.6
ContentType	Journal Article
Copyright	2021. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright 2021 Ku GY et al. .
Copyright_xml	– notice: 2021. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright 2021 Ku GY et al. .
DBID	ZGVWO AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM
DOI	10.1001/jamanetworkopen.2021.14753
DatabaseName	JAMA Network (Open Access) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One ProQuest Central Korea ProQuest Health & Medical Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Proquest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest One Health & Nursing ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic Publicly Available Content Database
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: ZGVWO name: JAMA Network (Open Access) url: https://jamanetwork.com sourceTypes: Publisher – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
DocumentTitleAlternate	Germline Alterations on Tumor-Normal Sequencing of Esophagogastric Cancer
EISSN	2574-3805
ExternalDocumentID	PMC8276088 34251444 10_1001_jamanetworkopen_2021_14753 2781910
Genre	Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NCI NIH HHS grantid: P30 CA008748
GroupedDBID	ZGVWO 0R~ 53G 7X7 8FI 8FJ AAYXX ABUWG ADBBV ADPDF AFFHD AFKRA ALMA_UNASSIGNED_HOLDINGS AMJDE BCNDV BENPR CCPQU CITATION EBS EMOBN FYUFA GROUPED_DOAJ H13 HMCUK OK1 OVD OVEED PHGZM PHGZT PIMPY RAJ TEORI UKHRP W2D ALIPV CGR CUY CVF ECM EIF M~E NPM 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-a473t-5eb65d154ca6b984b89cc44a17c61876394cf8a51a64e53717a93a5010c085123
IEDL.DBID	ZGVWO
ISICitedReferencesCount	23
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000673009500003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2574-3805
IngestDate	Tue Nov 04 01:57:49 EST 2025 Wed Oct 01 13:24:25 EDT 2025 Tue Oct 07 07:25:13 EDT 2025 Thu Apr 03 07:06:02 EDT 2025 Sat Nov 29 06:31:37 EST 2025 Tue Nov 18 22:15:59 EST 2025 Fri Jul 05 01:57:42 EDT 2024
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	7
Language	English
License	This is an open access article distributed under the terms of the CC-BY License.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-a473t-5eb65d154ca6b984b89cc44a17c61876394cf8a51a64e53717a93a5010c085123
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
OpenAccessLink	http://dx.doi.org/10.1001/jamanetworkopen.2021.14753
PMID	34251444
PQID	2668890276
PQPubID	5319538
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_8276088 proquest_miscellaneous_2550627063 proquest_journals_2668890276 pubmed_primary_34251444 crossref_citationtrail_10_1001_jamanetworkopen_2021_14753 crossref_primary_10_1001_jamanetworkopen_2021_14753 ama_primary_2781910
PublicationCentury	2000
PublicationDate	2021-07-01
PublicationDateYYYYMMDD	2021-07-01
PublicationDate_xml	– month: 07 year: 2021 text: 2021-07-01 day: 01
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: Chicago
PublicationTitle	JAMA Network Open
PublicationTitleAlternate	JAMA Netw Open
PublicationYear	2021
Publisher	American Medical Association
Publisher_xml	– name: American Medical Association
References	Johannsson (zoi210450r17) 1999; 35 Jakubowska (zoi210450r19) 2002; 87 zoi210450r10 Oliveira (zoi210450r3) 2015; 16 Cheng (zoi210450r6) 2015; 17 Hampel (zoi210450r4) 2015; 17 Bray (zoi210450r1) 2018; 68 Huang (zoi210450r16) 2015; 6 De Bono (zoi210450r23) 2020; 382 Ku (zoi210450r2) 2014; 30 O’Reilly (zoi210450r25) 2020; 38 Lowery (zoi210450r14) 2018; 110 Breast Cancer Linkage Consortium (zoi210450r18) 1999; 91 Hu (zoi210450r15) 2018; 319 Ravichandran (zoi210450r7) 2019; 21 Broeks (zoi210450r13) 2000; 66 Moore (zoi210450r21) 2018; 379 zoi210450r9 Daly (zoi210450r11) 2020 Richards (zoi210450r8) 2015; 17 Kalia (zoi210450r5) 2017; 19 Robson (zoi210450r22) 2017; 377 Moran (zoi210450r20) 2012; 11 Golan (zoi210450r24) 2019; 381 Cancer Genome Atlas Research Network (zoi210450r12) 2017; 541 34251447 - JAMA Netw Open. 2021 Jul 1;4(7):e2114789
References_xml	– volume: 319 start-page: 2401 issue: 23 year: 2018 ident: zoi210450r15 article-title: Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. publication-title: JAMA doi: 10.1001/jama.2018.6228 – volume: 6 start-page: 40953 issue: 38 year: 2015 ident: zoi210450r16 article-title: Prevalence of deleterious ATM germline mutations in gastric cancer patients. publication-title: Oncotarget doi: 10.18632/oncotarget.v6i38 – year: 2020 ident: zoi210450r11 – volume: 87 start-page: 888 issue: 8 year: 2002 ident: zoi210450r19 article-title: BRCA2 gene mutations in families with aggregations of breast and stomach cancers. publication-title: Br J Cancer doi: 10.1038/sj.bjc.6600562 – volume: 30 start-page: 596 issue: 6 year: 2014 ident: zoi210450r2 article-title: Management of gastric cancer. publication-title: Curr Opin Gastroenterol doi: 10.1097/MOG.0000000000000115 – volume: 66 start-page: 494 issue: 2 year: 2000 ident: zoi210450r13 article-title: ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. publication-title: Am J Hum Genet doi: 10.1086/302746 – volume: 381 start-page: 317 issue: 4 year: 2019 ident: zoi210450r24 article-title: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. publication-title: N Engl J Med doi: 10.1056/NEJMoa1903387 – volume: 38 start-page: 1378 issue: 13 year: 2020 ident: zoi210450r25 article-title: Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. publication-title: J Clin Oncol doi: 10.1200/JCO.19.02931 – volume: 382 start-page: 2091 issue: 22 year: 2020 ident: zoi210450r23 article-title: Olaparib for metastatic castration-resistant prostate cancer. publication-title: N Engl J Med doi: 10.1056/NEJMoa1911440 – volume: 17 start-page: 405 issue: 5 year: 2015 ident: zoi210450r8 article-title: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. publication-title: Genet Med doi: 10.1038/gim.2015.30 – volume: 19 start-page: 249 issue: 2 year: 2017 ident: zoi210450r5 article-title: Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. publication-title: Genet Med doi: 10.1038/gim.2016.190 – ident: zoi210450r10 – volume: 377 start-page: 523 issue: 6 year: 2017 ident: zoi210450r22 article-title: Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. publication-title: N Engl J Med doi: 10.1056/NEJMoa1706450 – volume: 17 start-page: 251 issue: 3 year: 2015 ident: zoi210450r6 article-title: Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. publication-title: J Mol Diagn doi: 10.1016/j.jmoldx.2014.12.006 – volume: 541 start-page: 169 issue: 7636 year: 2017 ident: zoi210450r12 article-title: Integrated genomic characterization of oesophageal carcinoma. publication-title: Nature doi: 10.1038/nature20805 – ident: zoi210450r9 – volume: 21 start-page: 2116 issue: 9 year: 2019 ident: zoi210450r7 article-title: Toward automation of germline variant curation in clinical cancer genetics. publication-title: Genet Med doi: 10.1038/s41436-019-0463-8 – volume: 16 start-page: e60 issue: 2 year: 2015 ident: zoi210450r3 article-title: Familial gastric cancer: genetic susceptibility, pathology, and implications for management. publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71016-2 – volume: 11 start-page: 235 issue: 2 year: 2012 ident: zoi210450r20 article-title: Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. publication-title: Fam Cancer doi: 10.1007/s10689-011-9506-2 – volume: 379 start-page: 2495 issue: 26 year: 2018 ident: zoi210450r21 article-title: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. publication-title: N Engl J Med doi: 10.1056/NEJMoa1810858 – volume: 17 start-page: 70 issue: 1 year: 2015 ident: zoi210450r4 article-title: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. publication-title: Genet Med doi: 10.1038/gim.2014.147 – volume: 110 start-page: 1067 issue: 10 year: 2018 ident: zoi210450r14 article-title: Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djy024 – volume: 35 start-page: 1248 issue: 8 year: 1999 ident: zoi210450r17 article-title: Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. publication-title: Eur J Cancer doi: 10.1016/S0959-8049(99)00135-5 – volume: 91 start-page: 1310 issue: 15 year: 1999 ident: zoi210450r18 article-title: Cancer risks in BRCA2 mutation carriers. publication-title: J Natl Cancer Inst doi: 10.1093/jnci/91.15.1310 – volume: 68 start-page: 394 issue: 6 year: 2018 ident: zoi210450r1 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. publication-title: CA Cancer J Clin doi: 10.3322/caac.v68.6 – reference: 34251447 - JAMA Netw Open. 2021 Jul 1;4(7):e2114789
SSID	ssj0002013965
Score	2.2868435
Snippet	IMPORTANCE: Among patients with esophagogastric cancers, only individuals who present with known features of heritable cancer syndromes are referred for... Among patients with esophagogastric cancers, only individuals who present with known features of heritable cancer syndromes are referred for genetic testing.... Importance Among patients with esophagogastric cancers, only individuals who present with known features of heritable cancer syndromes are referred for genetic... This genetic association study examines the prevalence of likely pathogenic or pathogenic germline alterations among patients with esophagogastric cancer and...
SourceID	pubmedcentral proquest pubmed crossref ama
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	e2114753
SubjectTerms	Adolescent Adult Aged Aged, 80 and over Cross-Sectional Studies Esophageal cancer Esophageal Neoplasms - epidemiology Esophageal Neoplasms - genetics Female Gastric cancer Germ-Line Mutation - genetics Humans Male Middle Aged Oncology Online Only Original Investigation Prevalence Whole Genome Sequencing - methods Whole Genome Sequencing - statistics & numerical data
SummonAdditionalLinks	– databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB7RhAMXngXcFrRIXC3wene9PlUlSsrJiiBIuZn1rlMipXZwkv7-zviVhkoVUs_2-jWzM9_sjr8P4LNTCKpNvvCd5MIXTme-EZn0NeY6YReCcmAtNhEliZ7P42m74LZp2yq7mFgHaldaWiP_golE055YpM7Xf31SjaLd1VZC4wiGxFQmBjD8Nk6mP_pVFk4IR8mebbShGyqaDmvSp8IKkQcYLiJSR95zrXb56R7o_Ld38k4ymrx47Gu8hOctDGUXjd-8gid58QZ-E5-Tqf9CYuWCXWLQJhDKLlY19TI5KCsLNqubx3PHZrvrsvITQr0r9rPpycZMSGPHpI5grsorQ7oglo3Iuapj-DUZz0bf_VaBAQ0WhVtf5pmSDlGWNSqLtch0bK0QJoisCojLLkZ7aiMDo0QuQywNTRwaiTWeJSjHw7cwKMoifw8ssI4LZ53SBmtK62KeO4FYyGWSIyyRHrzGr5-uG46NlEdUSX71IO6skdqWtJy0M1ZpQ7eMxcuhPVOyZ1rb04OwH9td9n9GnXWGS9vpvEn3VvPgU38YJyLtruCFyh2eg7We4hFCPg_eNT7S3zbEyIiVq_AgOvCe_gQi-T48Uiz_1GTfGm-KmeDk4cc6hWf0Ck0f8RkMttUu_wBP7c12uak-trPiFr26Gmc priority: 102 providerName: ProQuest
Title	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer
URI	http://dx.doi.org/10.1001/jamanetworkopen.2021.14753 https://www.ncbi.nlm.nih.gov/pubmed/34251444 https://www.proquest.com/docview/2668890276 https://www.proquest.com/docview/2550627063 https://pubmed.ncbi.nlm.nih.gov/PMC8276088
Volume	4
WOSCitedRecordID	wos000673009500003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2574-3805 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002013965 issn: 2574-3805 databaseCode: DOA dateStart: 20180101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: ProQuest - Health & Medical Complete保健、医学与药学数据库 customDbUrl: eissn: 2574-3805 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002013965 issn: 2574-3805 databaseCode: 7X7 dateStart: 20180101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2574-3805 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002013965 issn: 2574-3805 databaseCode: BENPR dateStart: 20180101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 2574-3805 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002013965 issn: 2574-3805 databaseCode: PIMPY dateStart: 20180101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swED9By8Ne2IB9ZLDKSLxGIo4dO4-ACtsDpYICHS-ZY6cMqUtQafn7uUvSqGUIIV4iRfGXzmff7-Lz7wD2XISg2mQj30kufOF06huRSl-jrRN2JMgGlskmVK-nh8O4v3Ap7PkJfsUPlFch0ZRQCl06HuD6Rpi9Cm2upJQtaN-cXF2fNZyir1VaZFSdW6H_oOXzCMkFk3P88X2D_QTrNcRkB5VObMBKlm_BH-JqMuUNI1aM2AluyAQw2cG4pFUm5WNFzgZlYHjm2GD2r5j4PUK0Y3ZRxVujlaO6Xcp8YG6LW0M5Pyw7IsWZfIbL4-7g6KdfZ1fAyVDh1JdZGkmHCMqaKI21SHVsrRAmUDYKiKcuxrnSRgYmEpkM0e0zcWgk-m-WYBoPv0ArL_LsG7DAOi6cdZE26C9aF_PMCcQ5LpUcIYf0YBPlktxX_BkJV-Ql7nsQz-cgsTUhOeXFGCcVlTI6JsvSTEiaSSlND8Km7rzZt9TamU91Ui_VhwQRiqbDVhV5sNt8xkVGJyfYUDHDMujHRVwhnPPga6UZTbch7nrolQoP1JLONAWIwHv5S373tyTy1tgp7vLfXxTPNnygkVehwTvQmk5m2Q9Ys4_Tu4dJB1bVUJVP3YH2YbfXP--U_xPwrf_rtP-7Uy-KJ4vcDd8
linkProvider	American Medical Association
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB5VWyS48H4EChgJjhHEsR3ngFBVWrpqu1qJRSqn1LG9pdKSlH2A-FP8RmbiJGVBQlx64Jw4ceJvZr6JJ98APHcKSbXx09hJLmLhdBkbUcpYY6wTdiooBjbNJrLRSB8f5-MN-NH9C0NllZ1PbBy1qy19I3-JgUTTnlim3px_ialrFO2udi00AiwO_PdvmLItXg_f4vq-4Hxvd7KzH7ddBXASWbqMpS-VdMgcrFFlrkWpc2uFMElmVUL6bDnOURuZGCW8TDHdMXlqJOYtlugJCR2gy98UCHY9gM3x8Gj8sf-qw4lRKdmrmwZ5oypUdFM_LMxIeYLuKaNuzBfarl08_IPk_l6r-Uvw27vxv722m3C9pdlsO9jFLdjw1R04Ib0q0_xlxeope4dBiUg225410tJkgKyu2KQpjveOTVaf63k8IlY_Y-9DzTlGehq7S90fzGl9aqjviWU7ZDzzu_DhUh7qHgyquvIPgCXWceGsU9pgzmxdzr0TyPVcKTnSLhnBbVzt4jxoiBQ8o0z5VQR5t_qFbUXZqTfIrAhy0picreOnIPwUDX4iSPux3WX_ZdRWB5SidVeL4gIlETzrD6Ojod0jvFC9wnMwl1U8Q0obwf2Ayf62KRoDZuYigmwNrf0JJGK-fqQ6-9SImWu8KUa6h3-f1lO4uj85OiwOh6ODR3CNHifUTG_BYDlf-cdwxX5dni3mT1qLZHBy2Wj-CXgddGY
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevalence+of+Germline+Alterations+on+Targeted+Tumor-Normal+Sequencing+of+Esophagogastric+Cancer&rft.jtitle=JAMA+network+open&rft.au=Ku%2C+Geoffrey+Y.&rft.au=Kemel%2C+Yelena&rft.au=Maron%2C+Steve+B.&rft.au=Chou%2C+Joanne+F.&rft.date=2021-07-01&rft.pub=American+Medical+Association&rft.eissn=2574-3805&rft.volume=4&rft.issue=7&rft_id=info:doi/10.1001%2Fjamanetworkopen.2021.14753&rft_id=info%3Apmid%2F34251444&rft.externalDocID=PMC8276088
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2574-3805&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2574-3805&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2574-3805&client=summon